Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study.
Rodríguez-Labrada RobertoRicardo Ortega-SanchezPatricia Hernández CasañaOrestes Santos MoralesMaria Del Carmen Padrón-EstupiñanMaricela Batista-NuñezDaise Jiménez RodríguezNalia Canales-OchoaArnoy Peña AcostaJacqueline Medrano MonteroPedro Enrique Labrada AguileraAnnelie Estupiñán RodriguezYaimee Vazquez-MojenaDennis Almaguer GotayJudey Aymed-GarcíaIdrian García-GarcíaReydenis Torres VegaCarmen Viada GonzálezCarmen M Valenzuela SilvaYanelis Silva RicardoJorge Columbié XimelisKenia Tribin RiveroRoselin Valle CabreraJulio Cesar García-RodriguezTania Crombet RamosDaniel Amaro-GonzálezTeresita Rodriguez-ObayaVelázquez-Pérez LuisPublished in: Movement disorders : official journal of the Movement Disorder Society (2022)
This study demonstrated the safety and tolerability of NeuroEPO in SCA2 patients after 6 months of treatments and suggested a small clinical effect of this drug on motor and cognitive abnormalities, but confirmatory studies are warranted. © 2022 International Parkinson and Movement Disorder Society.